<DOC>
	<DOCNO>NCT01743729</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy lifitegrast ophthalmic solution compare placebo treatment dry eye .</brief_summary>
	<brief_title>A Phase 3 Study Evaluate Efficacy Lifitegrast Subjects With Dry Eye</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Willing able read , sign date inform consent HIPAA document Willing able comply study procedure Be least 18 year age Patientreported history dry eye eye A negative urine pregnancy test female childbearing potential must use adequate birth control throughout study period Artificial tear use within past 30 day Any ocular condition , opinion Investigator , could affect study parameter include , limited , active ocular infection , ocular inflammation , glaucoma , and/or diabetic retinopathy Unwilling avoid wear contact lens 7 day prior first visit duration study Any blood donation significant loss blood within 56 day Visit 1 Any history immunodeficiency disorder , positive HIV , hepatitis B , C , evidence acute active hepatitis A ( antiHAV IgM ) , organ bone marrow transplant . Use prohibit medication time study unless otherwise specify Any significant illness could interfere study parameter History laser assist situ keratomileusis ( LASIK ) similar type corneal refractive surgery within 12 month prior first visit , and/or ocular surgical procedure within 12 month prior first visit ; schedule ocular surgical procedure study period . Known history alcohol and/or drug abuse Subjects Dry eye secondary scar destruction conjunctival goblet cell ( Vitamin A deficiency )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>SAR 1118</keyword>
</DOC>